May 27 (Reuters) - Mithra Pharmaceuticals SA MITRA.BR :
- NEXTSTELLIS RECEIVES FDA MARKETING EXCLUSIVITY AND PHASE III DATA PUBLISHED
- EXCLUSIVITY RUNS FOR FIVE YEARS FROM FDA APPROVAL OF THE NEW DRUG APPLICATION FOR NEXTSTELLIS
Source text: https://bit.ly/3wB8Nfp
News: MYX Mithra, Mayne Pharma's Nextstellis Receives FDA Marketing Exclusivity
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$4.95 |
Change
0.000(0.00%) |
Mkt cap ! $402.1M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2 | $5.21 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.65 | 65 | 1 |
View Market Depth
| Last trade - 09.39am 01/08/2025 (20 minute delay) ? |
| MYX (ASX) Chart |
Day chart unavailable